| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Desethylamiodarone HCl targets the same ion channels as its parent drug. Amiodarone is a class III antiarrhythmic agent that prolongs both cardiac action potential and refractoriness by blocking potassium currents. Desethylamiodarone HCl is a non-selective ion channel blocker and contributes to the overall pharmacological activity of Amiodarone.
|
|---|---|
| ln Vitro |
In vitro, Desethylamiodarone HCl is characterized as the main active metabolite of Amiodarone. It is formed by the CYP3A isoenzyme. As a non-selective ion channel blocker, it contributes to the antiarrhythmic effects of the parent drug. Its activity is similar to but not identical to Amiodarone.
|
| ln Vivo |
In vivo, Desethylamiodarone HCl is the main active metabolite formed following Amiodarone administration. It contributes to the overall therapeutic effect of Amiodarone in treating cardiac arrhythmias. Its role in vivo is primarily understood through pharmacokinetic and pharmacodynamic studies, where its concentration is correlated with antiarrhythmic efficacy and toxicity.
|
| Enzyme Assay |
In vitro assays for Desethylamiodarone HCl typically involve measuring its effects on ion channels. Patch-clamp electrophysiology is used to assess the compound's inhibition of potassium, sodium, or calcium channels. The compound's activity is compared to Amiodarone. Receptor binding studies can also be performed to assess its affinity for various targets.
|
| Cell Assay |
For in vitro cell-based assays, cardiomyocytes or cells expressing ion channels are cultured and treated with Desethylamiodarone HCl at various concentrations. Ion channel activity is measured using patch-clamp electrophysiology or fluorescence-based membrane potential assays. Cell viability is assessed by standard assays. The compound's effects on action potential duration and refractoriness are evaluated.
|
| Animal Protocol |
In vivo animal studies with Desethylamiodarone HCl are conducted in models of cardiac arrhythmias. The compound is administered orally or intravenously to animals. Electrocardiograms are recorded to assess the compound's effects on cardiac rhythm and refractoriness. Pharmacokinetic studies assess the formation and elimination of the metabolite following Amiodarone administration.
|
| ADME/Pharmacokinetics |
Desethylamiodarone HCl (CAS: 96027-74-6) has a molecular weight of 653.72 g/mol and a molecular formula of C23H25I2NO3·HCl. Chemical name: (2-butyl-1-benzofuran-3-yl)-[4-[2-(ethylamino)ethoxy]-3,5-diiodophenyl]methanone;hydrochloride. Appearance: solid powder. Melting Point: 176-178°C. Storage: -20°C.
|
| Toxicity/Toxicokinetics |
As a metabolite of Amiodarone, Desethylamiodarone HCl shares the toxicity profile of the parent drug. Amiodarone has significant side effects including pulmonary toxicity, hepatotoxicity, and thyroid dysfunction. The compound is used in research and analytical applications, not for direct human therapeutic use. Standard laboratory safety precautions should be followed.
|
| References |
|
| Additional Infomation |
Desethylamiodarone HCl (N-desethylamiodarone HCl) is the main active metabolite of Amiodarone, a class III antiarrhythmic agent. It is formed by the CYP3A isoenzyme. It has a molecular weight of 653.72 g/mol and a molecular formula of C23H25I2NO3·HCl. It is not FDA-approved as a standalone drug and is intended for research use only.
|
| Molecular Formula |
C23H25NO3I2.HCL
|
|---|---|
| Molecular Weight |
653.71844
|
| Exact Mass |
652.969
|
| CAS # |
96027-74-6
|
| Related CAS # |
Desethyl Amiodarone-d4 hydrochloride;1189960-80-2;Desethylamiodarone;83409-32-9
|
| PubChem CID |
178801
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
630.3ºC at 760 mmHg
|
| Melting Point |
176-178ºC
|
| Flash Point |
335ºC
|
| LogP |
7.396
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
30
|
| Complexity |
508
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
OCQPMJVGWGJLLG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H25I2NO3.ClH/c1-3-5-9-20-21(16-8-6-7-10-19(16)29-20)22(27)15-13-17(24)23(18(25)14-15)28-12-11-26-4-2;/h6-8,10,13-14,26H,3-5,9,11-12H2,1-2H3;1H
|
| Chemical Name |
(2-butyl-1-benzofuran-3-yl)-[4-[2-(ethylamino)ethoxy]-3,5-diiodophenyl]methanone;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~15.30 mM)
Ethanol : ~5 mg/mL (~7.65 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5297 mL | 7.6485 mL | 15.2971 mL | |
| 5 mM | 0.3059 mL | 1.5297 mL | 3.0594 mL | |
| 10 mM | 0.1530 mL | 0.7649 mL | 1.5297 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
